241 results on '"L. Potena"'
Search Results
2. C84 OUTCOME AND MORPHO–FUNCTIONAL CHANGES ON CARDIAC MAGNETIC RESONANCE IN PATIENT WITH ACUTE MYOCARDITIS FOLLOWING MRNA COVID 19 VACCINATION
- Author
-
M Palazzini, E Ammirati, L Lupi, A Garascia, P Gentile, P Pedrotti, C Giannattasio, M Ciabatti, V Rossi, F Ruschitzka, A Uribarri, C Vecchio, D Nassiacos, A Cereda, G Tumminiello, N Piriou, M Stucchi, G Peretto, M Galasso, S Sala, P Camici, F Huang, U Ianni, A Procopio, G Saponara, P Cimaglia, D Tomasoni, F Moroni, A Turco, G Di Tano, E Bollano, C Moro, A Abbate, R Dalla Bona, I Porto, S Carugo, J Campodonico, G Pontone, A Grosu, M Adamo, J Salamanca, K Ozieransky, L Sardo Infirri, A Cannatà, E Adler, G Sinagra, L Potena, A Foà, M Metra, and M Pieroni
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background MessengerRNA (mRNA) COVID–19 vaccination has been associated with a higher–than–expected occurrence of acute myocarditis. Scarce information is available on mid–term prognosis and changes in cardiac function, volumes, and tissue characterization on cardiac magnetic resonance (CMR). Methods Retrospective, multicenter study including patients with a definite diagnosis of acute myocarditis within 30 days from mRNA COVID–19 vaccination. The diagnosis is based on endomyocardial biopsy (EMB) or autopsy or by the coexistence of positive biomarkers (troponin >99th upper reference limit or elevated creatine kinase myocardial band [CK–MB]) and cardiac MRI findings consistent with AM according to the 2018 updated Lake Louise Criteria. Results 77 patients (median age 25 years [IQR 20–35], 15% female) were included and followed–up for 147 days [IQR 74–215]. Follow–up CMR was available in n=49 patients and showed no changes in biventricular ejection fraction (EF) as compared to CMR at diagnosis (left ventricular EF: 59%[55–65]vs. 60%[57–64], p=0.507, right ventricular EF: 56%[52–62]vs. 57%[52–61], p=0.563, respectively). Late gadolinium enhancement was present in all patients at diagnosis and persisted in only n=39 (79.6%) at follow–up (p=0.001), generally sparing the anterior wall and the septum. N=10 (20.4%) had a persistent edema based on T2–weighted short tau inversion recovery (STIR) sequences, with predominant involvement of inferior or inferior–lateral walls. The proportion of patients with increased T1 and T2 mapping signals significantly decreased at follow–up (n=13 (68%) vs. n=4 (13%),p Conclusions At mid–term follow–up, patients who experienced an acute myocarditis after a mRNA COVID–19 vaccine had preserved biventricular EF. The rate and localization of residual scar or edema on CMR is in line with classic viral myocarditis with a good prognosis. This new piece of information should further reassure patients who experience acute myocarditis after mRNA COVID–19 vaccination.
- Published
- 2023
3. (586) Trying to Protect HT Patients Poor Vaccine Responders: Reducing MMF or Trust Tixagevimab/Cilgavimab? Insights from CONTRAST Study
- Author
-
M. Masetti, M. Scuppa, L. Giovannini, L. Borgese, A. Aloisio, G. Spitaleri, M. Giannella, and L. Potena
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2023
4. Clinical profile and in-hospital outcome of patients supported by intra-aortic balloon pump in the clinical setting of cardiogenic shock according to aetiology
- Author
-
M Garofalo, A Corsini, L Potena, M Schinzari, E Nardi, F Barberini, C Gargiulo, M Malaguti, M Sabatino, F Semprini, N Galie, and S Nanni
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background Despite controversial evidence, intra-aortic balloon pump (IABP) is still the most used temporary mechanical support in cardiogenic shock (CS), as a bridge to recovery or to more advanced mechanical support and/or heart transplantation [1]. Indeed, the available evidence, which is mainly restricted to the context of acute coronary syndromes (ACS) and is limited by the variability of CS definitions, shows no benefit in terms of mortality [2]. Randomized controlled trials on IABP in the setting of non-ACS CS are still missing. As a result, European guidelines do not recommend the routine use of IABP, which may be considered in refractory CS [3]. Purpose The aim of our study was to analyse the use of IABP in the context of CS, providing insights into its indications, outcomes, and complications in relation to the aetiology (ACS vs non-ACS) of CS. Methods We retrospectively enrolled all consecutive adult patients receiving IABP for refractory CS at our tertiary referral Hospital between 2009 and 2018, and analysed data focusing on in-hospital outcomes, including death, recovery, heart transplantation, and escalation to more advanced mechanical support such as venoarterial extracorporeal membrane oxygenation (VA-ECMO) or left ventricular assist device (LVAD), and on IABP-related complications. Results 403 patients received IABP, 75.2% (n=303) for ACS CS and 24.8% (n=100) for non-ACS CS. With respect to ACS patients, non-ACS patients were younger (age 59±18.3 vs 73.1±12.6 years old, p0.05]. The incidence of IABP-related overall and major complications (including ischemic stroke, major bleeding, and peripheral or visceral ischemia) was not different with respect to the non-ACS vs ACS aetiology [major complications: 8.0% (n=8) vs 5.0% (n=15), p>0.05]. Conclusions In our experience, in the clinical setting of CS treated with IABP, non-ACS patients show a worse clinical profile and prognosis than ACS patients, and more often require escalation to more advanced mechanical support and/or heart transplantation, while the incidence of IABP-related complications appears similar independently of the aetiology. Funding Acknowledgement Type of funding sources: None.
- Published
- 2022
5. Predictors of early renal dysfunction after heart transplantation: a report from the International Consortium on Primary Graft Dysfunction
- Author
-
J Guzman Bofarull, J Han, Y Moayedi, L K Truby, F Foroutan, R Miller, L Potena, A Zuckermann, S Chih, M Farr, S Hall, H J Ross, K Khush, and M Farrero
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background Renal dysfunction is a common complication after heart transplantation (HT). Renal replacement therapy (RRT) after HT has been associated with increased risk of death. Long-term renal dysfunction is associated mainly to immunosuppressive therapy but is also strongly related to post-transplant renal failure. Predictors of early renal dysfunction after HT have not been clearly identified. Purpose We aimed to define predictors of early renal dysfunction after HT. Methods Our consortium includes 10 centers in the US, Canada and Europe. We collected data on all consecutive single-organ HT recipients from 2010 to 2020. The primary outcome was early renal dysfunction (ERD), defined as a composite of need for RRT or creatinine ≥2.5 mg/dL 24 hours after HT. We assessed the incidence of early renal dysfunction and performed univariate and multivariate analyses to identify the recipient and transplant characteristics associated with its development. Results We included 2,764 HT recipients: 282 (10.2%) presented early renal dysfunction and 2482 (89.8%) did not. Recipients who presented postoperative renal dysfunction were more frequently male, Caucasian, with previous sternotomy, higher baseline creatinine, longer ischemic time and worse donor LVEF. They were also more likely to be under RRT, intravenous inotropes or ECMO support and there was more incidence of severe primary graft dysfunction (PGD) (Table 1). Multi-variable logistic regression demonstrated that the strongest predictors for post-transplant renal dysfunction were development of severe PGD (OR 5.26, 2.88–9.62, p Conclusions Early renal dysfunction is a common complication after HT with an incidence around 10% in a large and contemporary cohort. The presence of PGD and need for RRT pre-transplant were the strongest predictors for its development. Interestingly, emergent transplantation or need for MCS were not independently associated with ERD. Further studies are needed to identify patients at high risk of early and late kidney dysfunction that may benefit from combined transplantation. Funding Acknowledgement Type of funding sources: None.
- Published
- 2022
6. C65 POST–DISCHARGE ARRHYTHMIC RISK STRATIFICATION OF PATIENTS WITH ACUTE MYOCARDITIS AND LIFE–THREATENING VENTRICULAR TACHYARRHYTHMIAS
- Author
-
P Gentile, M Merlo, G Peretto, E Ammirati, S Sala, P Della Bella, G Aquaro, M Imazio, L Potena, J Campodonico, A Foà, A Raafs, M Hazebroek, M Brambatti, A Cercek, G Nucifora, S Shrivastava, F Huang, M Schmidt, D Muser, C Van De Heyning, E Van Craenenbroeck, T Aoki, K Sugimura, H Shimokawa, A Cannatà, J Artico, A Porcari, M Colopi, R Bussani, G Barbati, A Garascia, M Cipriani, P Agostoni, N Pereira, S Heymans, E Adler, P Camici, M Frigerio, and G Sinagra
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Aims The outcomes of patients presenting with acute myocarditis and life–threatening ventricular arrhythmias (LT–VA) are unclear. The aim of this study was to assess the incidence and predictors of recurrent major arrhythmic events (MAEs) after hospital discharge in this patient population. Methods and Results We retrospectively analysed 156 patients (median age 44 years; 77% male) discharged with a diagnosis of acute myocarditis and LT–VA from 16 hospitals worldwide. Diagnosis of myocarditis was based on histology or the combination of increased markers of cardiac injury and cardiac magnetic resonance (CMR) Lake Louise criteria. MAEs were defined as the relapse, after discharge, of sudden cardiac death or successfully defibrillated ventricular fibrillation, or sustained ventricular tachycardia (sVT) requiring implantable cardioverter–defibrillator therapy or synchronized external cardioversion. Median follow–up was 23months [first to third quartile (Q1–Q3) 7–60]. Fifty–eight (37.2%) patients experienced MAEs after discharge, at a median of 8 months (Q1–Q3 2.5–24.0 months; 60.3% of MAEs within the first year). At multivariable Cox analysis, variables independently associated with MAEs were presentation with sVT [hazard ratio (HR) 2.90, 95% confidence interval (CI) 1.38–6.11]; late gadolinium enhancement involving ≥2 myocardial segments (HR 4.51, 95% CI 2.39–8.53), and absence of positive short–tau inversion recovery (STIR) (HR 2.59, 95% CI 1.40–4.79) at first CMR. Conclusions In this international multicentre study, patients discharged free from HTx or LVAD after an acute myocarditis complicated by LT–VA had a recurrence of MAEs during follow–up of 37.2%, after a median time of 8 months. Initial CMR pattern and sVT at presentation stratify the risk of arrhythmia recurrence.
- Published
- 2022
7. (169) Incidence and Predictors of Vasoplegia after Heart Transplantation: Results from the International PGD Consortium
- Author
-
J. Han, Y. Moayedi, L. Truby, F. Foroutan, J. Guzman Bofarull, S. Saha, P. Angleitner, M. Sabatino, E. Henricksen, H. Luikart, J. van Zyl, M. Tremblay-Gravel, P. Noly, J. Segovia-Cubero, E. Ródenas Alesina, L. Potena, K. Takeda, J. Felius, B. Clarke, A. DeVore, G. Kim, R. Miller, A. Zuckermann, M. Farr, M. Crespo-Leiro, S. Hall, M. Farrero Torres, C. Fan, H. Ross, K. Khush, and S. Chih
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2023
8. (42) Restrictive Physiology: Playing with Rhc Between Cav and Amr
- Author
-
M. Masetti, M. Scuppa, L. Giovannini, M. Sabatino, S. Martin Suarez, and L. Potena
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2023
9. Using Machine Learning to Develop a Contemporary Primary Graft Dysfunction Prediction Model: The International Consortium on PGD
- Author
-
Y. Moayedi, F. Foroutan, L.K. Truby, J. Han, P. Angleitner, J. Guzman, M. Sabatino, J. Felius, H. Zafar, D. Law, J. Van Zyl, M. Tremblay-Gravel, J. Segovia, A. Devore, G. Kim, M. Riva Lasarte, I. Knezevic, P. Noly, M. Farr, A. Zuckermann, L. Potena, M. Ferrero, R. Miller, S.C. Fan, S. Chih, S.A. Hall, K.K. Khush, and H.J. Ross
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
10. Bridge to Transplant with Durable Left Ventricular Assist Device is Associated with Primary Graft Dysfunction Following Heart Transplantation: A Report from the International Consortium on Primary Graft Dysfunction
- Author
-
L.K. Truby, Y. Moayedi, F. Foroutan, J. Han, J. Guzman, M. Farrero, H. Zafar, J. Felius, J. van Zyl, S. Hall, D. Law, S. Chih, P. Angleitner, M. Sabatino, A. DeVore, R. Miller, L. Potena, A. Zuckermann, H. Ross, K. Khush, and M. Farr
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
11. Impact of Recipients Pre-Operative Right Ventricular Dysfunction on Heart Transplantation Outcomes
- Author
-
A. Loforte, F. Fiorentino, G. Gliozzi, V. Santamaria, G. Cavalli, G. Murana, C. Mariani, L. Botta, M. Sabatino, M. Masetti, L. Potena, S. Martin Suarez, and D. Pacini
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
12. Using Hemodynamics to Define Graft Function: Do We Need It?
- Author
-
M. Masetti, F. Scuppa, M. Sabatino, S. Martin Suarez, A. Loforte, A. Russo, P. Prestinenzi, O. Leone, and L. Potena
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
13. Cardiac Transplantation Italian Allocation System Analysis: Single Center Results
- Author
-
M. Fiorentino, S. Martin Suarez, L. Botta, A. Loforte, G. Murana, C. Amodio, A. Costantino, G. Cavalli, S. Tassi, A. Russo, M. Masetti, L. Potena, and D. Pacini
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
14. Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients
- Author
-
M. Masetti, A. Aloisio, L. Giovannini, L. Borgese, N. Caroccia, R. Pascale, T. Lazzarotto, M. Giannella, D. Pacini, P. Viale, and L. Potena
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
15. Medium-Long Term Results of Cardiac Transplantation from Donors Assessed with the 'Aged Donor Heart Rescue by Stress Echo' (ADONHERS) Protocol
- Author
-
S. Martin Suarez, M. Fiorentino, G. Murana, L. Botta, A. Loforte, V. Santamaria, V. Pagano, P. Prestinenzi, M. Sabatino, A. Bombardini, G. Sangiorgi, L. Potena, and D. Pacini
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2022
16. Moderated Posters session * Insights into the use of contrast stress echocardiography and 3D strain: 14/12/2013, 08:30-12:30 * Location: Moderated Poster area
- Author
-
D. Muraru, E. Piasentini, S. Mihaila, P. Naso, S. Casablanca, D. Peluso, G. Denas, L. Ucci, S. Iliceto, L. Badano, S. S. Abdel Moneim, B. Kirby, E. Mendrick, B. Norby, M. Hagen, A. Basu, S. Mulvagh, R. Chelliah, G. Whyte, S. Sharma, A. Pantazis, R. Senior, D. Grishenkov, S. Kothapalli, A. Gonon, B. Janerot-Sjoberg, S. Gianstefani, P. Maccarthy, T. Rogers, A. Sen, I. Delithanasis, J. Reiken, L. Charangwa, A. Douiri, M. Monaghan, T. Bombardini, R. Sicari, S. Gherardi, Q. Ciampi, L. Pratali, S. Salvadori, E. Picano, B. Shivalkar, P. Belkova, K. Wouters, C. Van De Heyning, C. De Maeyer, P. Van Herck, C. Vrints, D. Voilliot, J. Magne, R. Dulgheru, C. Henri, S. Kou, S. Laaraibi, M. Sprynger, B. Andre, L. Pierard, P. Lancellotti, M. Federspiel, E. Oger, M. Fournet, M. Daudin, C. Thebault, E. Donal, G. Arpesella, S. Bernazzali, L. Potena, W. Serra, and R. Del Bene
- Subjects
medicine.medical_specialty ,3d strain ,business.industry ,media_common.quotation_subject ,General Medicine ,Internal medicine ,medicine ,Cardiology ,Stress Echocardiography ,Contrast (vision) ,Radiology, Nuclear Medicine and imaging ,Session (computer science) ,Cardiology and Cardiovascular Medicine ,business ,media_common - Published
- 2013
17. Folate supplementation after heart transplantation: effects on homocysteine plasma levels and allograft vascular disease
- Author
-
L, Potena, F, Grigioni, G, Magnani, S, Sorbello, S, Sassi, M G, Poci, S, Carigi, L, Bacchi-Reggiani, O, Leone, C, Magelli, A, Branzi, and G, Magnai
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Homocysteine ,Diet therapy ,medicine.medical_treatment ,Hyperhomocysteinemia ,Coronary Angiography ,Critical Care and Intensive Care Medicine ,Gastroenterology ,chemistry.chemical_compound ,Folic Acid ,Internal medicine ,Blood plasma ,medicine ,Humans ,Transplantation, Homologous ,Prospective Studies ,Vascular Diseases ,Heart transplantation ,Creatinine ,Nutrition and Dietetics ,business.industry ,Vascular disease ,Folate supplementation ,Middle Aged ,medicine.disease ,Transplantation ,Endocrinology ,chemistry ,Dietary Supplements ,Heart Transplantation ,Female ,business ,Follow-Up Studies - Abstract
Background and aims: After heart transplantation, the effects of folate supplementation on total homocysteine plasma levels (THcy) and heart allograft vascular disease (AVD) remain unclear. Methods: Accordingly, we prospectively analyzed 48 heart transplant receipients referred for routine follow-up from July to September 1998 (age 54±11 years, 75% male, 35±27 months from transplant). Among these patients, 17 were treated with folate supplementation for 12 months (Group F), while 31 cross-matched for age, gender, serum creatinine and time from transplant (P>0.3 vs Group F for all) did not assume folate supplementation (Group NF). Routine coronary angiography for AVD detection was routinely obtained in every patient. Results: THcy overall increased during the study period (from 16.6±6.5 to 19.4±7.6 μmol/l, P
- Published
- 2002
18. Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Outcome, Treatment Strategies and Analysis of Risk Factors
- Author
-
A. Loforte, E. Pilato, S. Martin Suarez, G. Jafrancesco, S. Castrovinci, M. Cefarelli, L. Potena, M. Masetti, G. Magnani, F. Grigioni, G. Frascaroli, and G. Marinelli
- Subjects
Pulmonary and Respiratory Medicine ,Transplantation ,Surgery ,Cardiology and Cardiovascular Medicine - Published
- 2015
19. L’INFEZIONE DA CITOMEGALOVIRUS UMANO NEI PAZIENTI TRAPIANTATI DI CUORE: MONITORAGGIO VIROLOGICO ED IMMUNOLOGICO
- Author
-
P. Monari, C. Magelli, T. Lazzarotto, L. Gabrielli, G. Piccirilli, Angela Chiereghin, S. Pop, C. Grandi, Maria Paola Landini, and L. Potena
- Subjects
lcsh:QR1-502 ,lcsh:Microbiology - Published
- 2007
20. Ruolo residuo della terapia medica e con device nei pazienti affetti da scompenso cardiaco cronico riferiti per trapianto
- Author
-
A. Scalone, M. Pizzuti, M. Masetti, G. Bianchi, G. Piovaccari, L. Potena, RUSSO, ANTONIO, F. Coccolo, F. Fallani, G. Magnani, BORIANI, GIUSEPPE, GRIGIONI, FRANCESCO, BRANZI, ANGELO, A.Scalone, M.Pizzuti, M.Masetti, G.Bianchi, G.Piovaccari, L.Potena, A.Russo, F.Coccolo, F.Fallani, G.Magnani, G.Boriani, F.Grigioni, and A.Branzi
- Published
- 2007
21. 169 Interplay between Pulmonary Hypertension and Donor-Recipient Matching in the Risk for Early Graft Failure after Heart Transplantation
- Author
-
L. Potena, S. Martin-Suarez, V. Manfredini, M. Masetti, E. Pilato, G. Magnani, F. Fallani, F. Coccolo, A. Russo, F. Grigioni, A. Branzi, and G. Arpesella
- Subjects
Pulmonary and Respiratory Medicine ,Heart transplantation ,Transplantation ,medicine.medical_specialty ,Matching (statistics) ,Graft failure ,business.industry ,medicine.medical_treatment ,medicine.disease ,Pulmonary hypertension ,Internal medicine ,medicine ,Cardiology ,Surgery ,Cardiology and Cardiovascular Medicine ,business - Published
- 2012
22. [Familial predisposition to ischemic cardiopathy: role of homocysteine and genetic polymorphism of methylenetetrahydrofolate reductase]
- Author
-
L, Potena, F, Grigioni, V, Mantovani, G, Magnani, C, Magelli, and A, Branzi
- Subjects
Causality ,Oxidoreductases Acting on CH-NH Group Donors ,Polymorphism, Genetic ,Risk Factors ,Myocardial Ischemia ,Humans ,Homocysteine ,Methylenetetrahydrofolate Reductase (NADPH2) - Abstract
Homocysteine represents a risk factor for coronary artery disease determined not only by nutritional habits, but also by the genetic polymorphism of the enzymes involved in its metabolism (i.e. methylenetetrahydrofolate reductase - MTHFR). However, recent prospective studies questioned the initial evidence of a clear epidemiological and pathogenetic link between homocysteine levels and coronary artery disease. Moreover, the relationships between MTHFR polymorphism and coronary artery disease remain unclear. In this paper, the recent literature analyzing the role of homocysteine and MTHFR polymorphism as a risk factor for coronary artery disease has been reviewed.
- Published
- 2001
23. Increasing plasma homocysteine during follow-up in heart transplant recipients: effects of folate and renal function
- Author
-
L, Potena, F, Grigioni, G, Magnani, S, Sorbello, S, Sassi, L, Marinucci, R, Conti, V, Carinci, O, Leone, G, Arpesella, S, Coccheri, C, Magelli, and A, Branzi
- Subjects
Male ,Folic Acid ,Creatinine ,Cyclosporine ,Heart Transplantation ,Humans ,Female ,Prospective Studies ,Middle Aged ,Kidney ,Homocysteine ,Immunosuppressive Agents ,Follow-Up Studies - Abstract
Hyperhomocysteinemia is a common finding in heart transplant recipients and may represent a risk factor for graft failure. However, the time-course, determinants and effects of medical therapy on total homocysteine plasma levels after heart transplantation remain undetermined. The aim of this study was to prospectively analyze 1) the time-course of total homocysteine in heart transplant recipients; 2) the effects of folate supplements and cyclosporine A on total homocysteine; 3) the relation among renal function, serum vitamin levels, and total homocysteine.Fifty-two heart transplant recipients consecutively evaluated for routine follow-up during 1998 were included in the study (mean age 54 +/- 12 years; 28% female). Among the 52 patients, 10 patients were treated with folate for the entire period of the study (Group F), while 26 patients never received folate (Group NF). The remaining 16 patients who did not take folate on a regular basis were excluded from subgroup analysis. Total homocysteine and creatinine plasma levels were assayed at entry into the study (time 0) and at the end of the study, 12 months later (time 12).Homocysteinemia increased significantly from time 0 to time 12 (p0.001), regardless of creatinine plasma levels (p = 0.03) and folate intake (p0.01). However, total homocysteine levels were lower in Group F compared to Group NF at time 0 and time 12 (p0.02). On multivariate analysis, time of follow-up, serum creatinine and lack of folate intake were positive independent predictors of total homocysteine.Homocysteinemia increased over time in heart transplant recipients, regardless of renal function and folate administration. Lower total homocysteine levels were associated with folate intake, suggesting that folate supplements may play a role in the prevention of vascular allograft disease.
- Published
- 2000
24. Distance between Patients Subjective Perceptions and Objectively Evaluated Disease Severity in Chronic Heart Failure.
- Author
-
F. Grigioni, S. Carigi, S. Grandi, L. Potena, F. Coccolo, L. Bacchi-Reggiani, G. Magnani, E. Tossani, A.C. Musuraca, C. Magelli, and A. Branzi
- Subjects
HEART failure ,QUALITY of life ,CORONARY disease ,DISEASE management ,COST effectiveness ,ALTERNATIVE medicine - Abstract
AbstractBackground: Chronic heart failure (CHF) is a socially relevant condition carrying an adverse prognosis. Systematic analysis is needed of the relationship between quality of life (QoL) what patients are most interested in and objective parameters of CHF severity which largely determines physicians care. Methods: We prospectively investigated QoL, as ascertained by the Minnesota Living with Heart Failure Questionnaire, alongside all the currently used objective clinical/instrumental (electrocardiographic, echocardiographic, hemodynamic and functional capacity) indicators of disease severity in 106 consecutive CHF patients. Results: Besides persistence of sinus rhythm (p = 0.007), the only objective parameters that correlated with QoL were NYHA class (p < 0.001) and distance covered during the six minutes walking test (p < 0.001) (two indications of patients ability to attend to their daily needs). Presence of left bundle branch block was associated with a worse QoL only in patients with CHF due to ischemic heart disease (p = 0.032). All the other clinical/instrumental parameters showed no relation with QoL (p > 0.150 in all cases). Conclusions: Objective indicators of disease severity, which largely determine physicians care, appear to have little bearing on QoL, suggesting that current treatment for CHF fails to satisfy patients perceived needs. The possibility of cost-effective nonpharmaceutical therapeutic protocols (e.g. psychological interventions) specifically designed to improve patients QoL deserves investigation as a much needed new approach to the management of CHF.Copyright © 2003 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
25. Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes
- Author
-
Egidio Stigliano, Sandra Pasquini, Roberta Fiaccavento, Giovanni Monego, Luciano Potena, Paolo Di Nardo, Vincenzo Arena, Franco O. Ranelletti, Giorgio Arpesella, Arnaldo Capelli, Ornella Leone, G. Monego, V. Arena, S. Pasquini, E. Stigliano, R. Fiaccavento, O. Leone, G. Arpesella, L. Potena, F.O. Ranelletti, P. Di Nardo, and A. Capelli
- Subjects
Male ,Physiology ,Myocardial Ischemia ,Parathyroid hormone ,Fluorescent Antibody Technique ,Settore MED/11 - Malattie dell'Apparato Cardiovascolare ,Muscle hypertrophy ,Medicine ,Myocyte ,Myocytes, Cardiac ,Receptor ,Child ,cellular distribution ,Aged, 80 and over ,Middle Aged ,Immunohistochemistry ,coronary artery atherosclerosis ,Child, Preschool ,Female ,Hypertrophy, Left Ventricular ,hypertrophy ,Cardiology and Cardiovascular Medicine ,ischemic injury ,hormones, hormone substitutes, and hormone antagonists ,Adult ,medicine.medical_specialty ,heart muscle ischemia ,Adolescent ,cardiac ,PTHrP ,Heart Ventricles ,Ischemia ,heart muscle cell ,heart ,Contractility ,Young Adult ,Physiology (medical) ,Internal medicine ,Humans ,right ventricular ,Aged ,Receptor, Parathyroid Hormone, Type 1 ,PTH1R ,Hypertrophy, Right Ventricular ,business.industry ,Parathyroid Hormone-Related Protein ,medicine.disease ,Endocrinology ,parathyroid hormone receptor 1 ,adolescent ,adult ,hypertrophy, left ventricular ,hypertrophy, right ventricular ,left ventricular ,business ,Immunostaining - Abstract
The PTHrP/PTH1R signalling system induces calciotropic and myorelaxant effects on the vascular system and plays critical roles in the development of the cardiovascular system. In animal models, PTHrP exerts important effects on heart rate and contractility, particularly under ischemic conditions, while, in human hearts, the expression of PTHrP by cardiomyocytes remains to be defined in both normal and ischemic conditions. The present study has been conducted on 101 autoptical cases and confirmed on nine explanted hearts in order to analyze the expression of the PTHrP/PTH1R system by ventricular myocardium in respect to morphological aspects of the myocardial ischemic damage, myofiber hypertrophy and disarray, coronarosclerosis, age and sex. Immunohistochemistry showed positive cytoplasmic immunostaining for both PTHrP and PTH1R in ventricular cardiomyocytes. The expression levels of the PTHrP/PTH1R system resulted significantly increased (P = 0.0008 and P < 0.0001, respectively) in association with the myocardial ischemic damage and the presence of cardiomyocyte hypertrophy (P = 0.02 and P = 0.009 respectively). Conversely, increased expression levels of PTHrP alone were observed in myofiber disarray (P = 0.04), whereas PTH1R was augmented in coronarosclerosis (P = 0.004) and age (P = 0.001). Taken together, these results demonstrate that human ventricular cardiomyocytes express PTHrP and PTH1R and suggest that the activation of the PTHrP/PTH1R system could represent an aspect of the embryonic gene program typically reactivated by the myocardium when subjected to ischemia and/or hypertrophy.
- Published
- 2008
26. Insufficienza mitralica organica: parametri ecocardiografici, funzionali e neuro-ormonali potenziali predittori di intervento chirurgico a breve termine
- Author
-
M. Pizzuti, E. Cepeli, RUSSO, ANTONIO, BIANCHI, ISIDORO GIORGIO, MASETTI, MARCO, POTENA, LUCIANO, GRIGIONI, FRANCESCO, BRANZI, ANGELO, LEONARDO BOLOGNESE, M. Pizzuti, A. Russo, E. Cepeli, I.G. Bianchi, M. Masetti, L. Potena, F. Grigioni, and A. Branzi
- Published
- 2008
27. Il rallentamento del flusso di perfusione coronarica valutato con il TIMI frame count è in grado di predire la mortalità a lungo termine nei pazienti con trapianto di cuore
- Author
-
BIGLIARDI, MAURO, POTENA, LUCIANO, MAGNANI, GAIA, IONICO, TERESA, RUSSO, ANTONIO, ORTOLANI, PAOLO, GRIGIONI, FRANCESCO, ARPESELLA, GIORGIO, BRANZI, ANGELO, D. Fiore, F. Fallani, LEONARDO BOLOGNESE, M. Bigliardi, L. Potena, G. Magnani, T. Ionico, D. Fiore, A. Russo, F. Fallani, P. Ortolani, F. Grigioni, G. Arpesella, and A. Branzi
- Published
- 2008
28. Le complicanze metaboliche post-trapianto di cuore ruolo dell'adiponectina ed associazione con la malattia coronarica del graft
- Author
-
QUARTA, CANDIDA CRISTINA, POTENA, LUCIANO, MAGNANI, GAIA, ORTOLANI, PAOLO, MASETTI, MARCO, PIOVACCARI, GIULIA, GRIGIONI, FRANCESCO, BRANZI, ANGELO, F. Angeli, F. Fallani, LEONARDO BOLOGNESE, C.C. Quarta, L. Potena, G. Magnani, F. Angeli, P. Ortolani, M. Masetti, G. Piovaccari, F. Fallani, F. Grigioni, and A. Branzi
- Published
- 2008
29. Correlazione tra metodi semiquantitativi e quantitativi nella valutazione dell'insufficienza mitralica organica ed associazione con test da sforzo cardiopolmonare e pro-BNP
- Author
-
M. Pizzuti, E. Cepeli, RUSSO, ANTONIO, BIANCHI, ISIDORO GIORGIO, MASETTI, MARCO, POTENA, LUCIANO, GRIGIONI, FRANCESCO, BRANZI, ANGELO, LEONARDO BOLOGNESE, M. Pizzuti, A. Russo, I.G. Bianchi, E. Cepeli, M. Masetti, L. Potena, F. Grigioni, and A. Branzi
- Published
- 2008
30. Reproducibility of IVUS Measurements in Heart Transplant Recipients: Increased Quality of Data by Using Dedicated Software for Image Analysis
- Author
-
Luciano Potena, F. Fabbri, V. D'Errico, Gaia Magnani, Isidoro Giorgio Bianchi, D. Fiore, Angelo Branzi, Paolo Ortolani, Francesco Grigioni, Romano Zannoli, Ivan Corazza, V D'Errico, L Potena, D Fiore, F Fabbri, F Grigioni, G Magnani, P Ortolani, I Bianchi, I Corazza, R Zannoli, and A Branzi
- Subjects
Heart transplantation ,medicine.medical_specialty ,Reproducibility ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Computer Science Applications1707 Computer Vision and Pattern Recognition ,Gold standard (test) ,Limiting ,Cardiac allograft vasculopathy ,medicine.anatomical_structure ,Internal medicine ,Intravascular ultrasound ,medicine ,Cardiology ,cardiovascular system ,Radiology ,Thickening ,business ,Cardiology and Cardiovascular Medicine ,Artery - Abstract
Cardiac allograft vasculopathy (CAV) is the major cause limiting long term graft survival after heart transplantation (HT), and is characterized by changes in coronary artery geometry, such as intimal thickening and vessel remodeling. Given the limited strategies available to reduce its impact on outcome, early diagnosis of CAV - for which intravascular ultrasound (IVUS) is the gold standard - is crucial to appropriately modulate therapy and to reduce contributing risk factors. However, a highly reproducible image-analysis method is required to capture the complex mechanisms beyond CAV - related changes in coronary geometry.
- Published
- 2008
31. Prophylaxis vs. Pre-Emptive Strategies in Preventing Cytomegalovirus-Dependent Cardiac Allograft Vasculopathy
- Author
-
POTENA, LUCIANO, MUSURACA, ANNA CHIARA, GRIGIONI, FRANCESCO, ORTOLANI, PAOLO, MAGNANI, GAIA, RUSSO, ANTONIO, BRANZI, ANGELO, G. Pastorelli, F. Angeli, M. G. Vetrugno, F. Fallani, F. Coccolo, L. Potena, A.C. Musuraca, F. Grigioni, P. Ortolani, G. Pastorelli, F. Angeli, M.G. Vetrugno, G. Magnani, F. Fallani, F. Coccolo, A. Russo, and A. Branzi
- Published
- 2008
32. Efficacia e sicurezza dell'ezetimibe in associazione con basse dosi di simvastatina per il trattamento dell'iperlipidemia post-trapianto cardiaco
- Author
-
QUARTA, CANDIDA CRISTINA, MASETTI, MARCO, BIANCHI, ISIDORO GIORGIO, MUSURACA, ANNA CHIARA, POTENA, LUCIANO, GRIGIONI, FRANCESCO, MAGNANI, GAIA, RUSSO, ANTONIO, BRANZI, ANGELO, A. Scalone, M. Pizzuti, F. Fabbri, GIUSEPPE AMBROSIO, C.C. Quarta, M. Masetti, I.G. Bianchi, A. Scalone, M. Pizzuti, F. Fabbri, A.C. Musuraca, L. Potena, F. Grigioni, G. Magnani, A. Russo, and A. Branzi
- Published
- 2007
33. Prevalence of substance-related disorders in heart transplantation candidates
- Author
-
Eliana Tossani, Luciano Potena, Carlo Magelli, Francesco Grigioni, Laura Sirri, Marco Masetti, Angelo Branzi, Silvana Grandi, L. Sirri, L. Potena, M. Masetti, E. Tossani, F. Grigioni, C. Magelli, A. Branzi, and S. Grandi
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Waiting Lists ,Substance-Related Disorders ,Caffeine intoxication ,Health Status ,medicine.medical_treatment ,Alcohol abuse ,Lifestyle modification ,Epidemiology ,Prevalence ,medicine ,Humans ,Psychiatry ,Aged ,Retrospective Studies ,Heart transplantation ,Transplantation ,business.industry ,Middle Aged ,medicine.disease ,Tissue Donors ,Substance abuse ,Italy ,Heart failure ,Heart Transplantation ,Female ,Surgery ,business - Abstract
Substance abuse cessation is one of the leading factors in determining the eligibility for the heart transplantation waiting list, as noncompliance with this issue may seriously endanger posttransplantation outcomes. Yet, the prevalence of substance-related disorders among candidates for heart transplantation has not been evaluated enough. Eighty three heart transplantation candidates were assessed for prior or current substance-related disorders through the Structured Clinical Interview for mental disorders according to DSM-IV. A prior history of at least one substance-related disorder was found in 64% of patients, with nicotine dependence as the most prevalent diagnosis (61.4% of the sample). Ten subjects were currently smokers, despite heart failure. A prior history of alcohol abuse and caffeine intoxication was found in 9.6% and 2.4% of patients, respectively. Substance abuse or dependence behaviors should be monitored during all the phases of heart transplantation program. Early identification of current substance-related disorders may allow better allocation of organ resources and proper lifestyle modification programs provision. A prior history of substance-related disorders should alert physicians to assess patients for possible relapse, especially after transplantation. The inclusion of a specialist in the assessment and treatment of substance-related disorders in the heart transplantation unit may reduce the risk of unsuccessful outcomes due to noncompliance with an adequate lifestyle.
- Published
- 2007
34. Late Changes in Maximal Intimal Thickness after Heart Transplant: Prognostic Implications and Risk Factors
- Author
-
Francesco Grigioni, Luciano Potena, C. Lonetti, Isidoro Giorgio Bianchi, Nevio Taglieri, Marco Masetti, P. Prestinenzi, Angelo Branzi, Gaia Magnani, Antonio Russo, V. Pece, M. Masetti, L. Potena, V. Pece, P. Prestinenzi, I. G. Bianchi, C. Lonetti, N. Taglieri, A. Russo, G. Magnani, F. Grigioni, and A. Branzi
- Subjects
Pulmonary and Respiratory Medicine ,Heart transplantation ,Transplantation ,medicine.medical_specialty ,Pathology ,Lumen volume ,Cardiac allograft ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Incidence (epidemiology) ,Metabolic risk ,medicine.disease ,HEART TRANSPLANTATION ,Insulin resistance ,RISK FACTORS ,Internal medicine ,Intravascular ultrasound ,medicine ,Cardiology ,Surgery ,In patient ,Cardiology and Cardiovascular Medicine ,business - Abstract
Purpose Intravascular ultrasound (IVUS) provides unique prognostic information on allograft vasculopathy progression by detecting increase in maximal intimal thickness (MIT) during the first post-heart transplant (HT) year. Later changes in coronary morphology, their prognostic relevance, and risk factors are however unexplored. Methods and Materials We investigated whether changes in coronary morphology assessed in patients receiving serial IVUS at 1 and 5 years after HT predicted fatal and non-fatal cardiovascular (CV) events. We additionally analyzed the impact of metabolic risk factors on changes in IVUS measurements. Results 107 consecutive patients receiving HT between 1999 and 2007 entered the study. During the 11 years of follow-up, incidence of CV death was 8±3% and of CV events was 26±6%. Between year 1 and 5, MIT and intimal volume increased, lumen volume decreased (P Figure ). Among the metabolic parameters, increasing triglycerides and HDL-cholesterol ≤65mg/dl predicted MIT increase ≥ 0.35 mm (P≤0.05). Conclusions This study provides the first suggestive evidence that MIT increase represent a relevant prognostic marker also after the first year after HT. In addition, the finding that clinically relevant MIT is predicted by lipid pattern typical of insulin resistance, provide a strong rationale supporting aggressive therapeutic interventions against metabolic abnormalities mid and long-term after HT.
- Published
- 2013
35. Clinical and Prognostic Correlates of pAMR Grading in Patients with Suspect Antibody Mediated Rejection
- Author
-
S. Iannelli, F. Fruet, P. Prestinenzi, L. Borgese, Ornella Leone, V. Manfredini, Francesco Grigioni, Gaia Magnani, Andrea Bontadini, Luciano Potena, M. Fanizza, Angelo Branzi, L. Borgese, M. Fanizza, L. Potena, O. Leone, A. Bontadini, S. Iannelli, F. Fruet, P. Prestinenzi, V. Manfredini, G. Magnani, F. Grigioni, and A. Branzi
- Subjects
Pulmonary and Respiratory Medicine ,Heart transplantation ,Transplantation ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,medicine.medical_treatment ,Hemodynamics ,Surgery ,HEART TRANSPLANTATION ,REJECTION ,Internal medicine ,Cohort ,Biopsy ,medicine ,Cardiology ,Clinical significance ,Cardiology and Cardiovascular Medicine ,Pulmonary wedge pressure ,business ,Grading (tumors) ,Pathological - Abstract
Purpose Antibody mediated rejection (AMR) is a serious emerging issue in the management of heart transplant (HT) recipients. Although consensus criteria currently define pathological diagnosis of AMR (pAMR), the clinical drawbacks of the pAMR criteria in term of graft function and prognosis, as well as pAMR relationship with donor specific antibodies, (DSA) are unexplored. Methods and Materials In this study we analyze the correlation between pAMR grading, hemodynamic features, DSA detection, and subsequent prognosis in a cohort of consecutive HT recipients with suspected AMR. Results We included 184 patients, with estimated 7-year graft survival of 84±4%, after biopsy. Luminex assay was available in 86 patients, of whom 24 (28%) positive for DSA. pAMR was diagnosed in 72 (39%) recipients (61, pAMR1 and 11 pAMR2). Capillary wedge pressure was higher in patients with pAMR≥1 than in those with pAMR 0 (P=0.03) but we found no difference in hemodynamic data between pAMR 1 and 2. Patients with DSA had a lower cardiac output (P=0.02). However, DSA did not correlate with pAMR grading, but were more often detected in patients with mixed rejection (cellular and AMR), than in those with pAMR alone (P=0.03). Significant angiographic vasculopathy (CAV) accounted for 30% of total deaths, regardless of any rejection grade, and was associated with 12% yearly mortality. pAMR grading per se, on the other hand, was not associated with graft survival, while mixed rejection accounted for a 3.6 times increased risk of graft-related death, in patients without CAV (P=0.04). Conclusions While showing that pathological signs of AMR were associated with a worse hemodynamic profile, with however no differences between pAMR 1 and 2 grades, this study provide suggestive evidence that DSA co-activate both cellular and antibody-mediated graft injury, and that mixed rejection, not AMR alone, drives poor outcome. These data shed new light on the clinical significance of pAMR grading, and brings attention to the adverse consequences of mixed rejection, as opposed to “pure” AMR.
- Published
- 2013
36. Extracorporeal Membrane Oxygenation Support System as Bridge to Solution in Refractory Cardiogenic Shock
- Author
-
Antonio Loforte, F. Musumeci, P. Lilla Della Monica, Giuseppe Marinelli, Luciano Potena, Sofia Martin-Suarez, Guido Frascaroli, Emanuele Pilato, Francesco Grigioni, A. Menichetti, Andrea Montalto, Giorgio Arpesella, A. Loforte, E. Pilato, S. Martin-Suarez, A. Montalto, P .Lilla Della Monica, L. Potena, F. Grigioni, G. Marinelli, G. Frascaroli, A. Menichetti, F. Musumeci, and G. Arpesella
- Subjects
Pulmonary and Respiratory Medicine ,Heart transplantation ,Transplantation ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Cardiogenic shock ,Hemodynamics ,medicine.disease ,law.invention ,Surgery ,Extracorporeal Membrane Oxygenation ,surgical procedures, operative ,law ,Anesthesia ,Heart failure ,Ventricular assist device ,medicine ,Cardiopulmonary bypass ,Extracorporeal membrane oxygenation ,Myocardial infarction ,CARDIOGENIC SHOCK ,Cardiology and Cardiovascular Medicine ,business - Abstract
Purpose The RotaFlow (Maquet, Jostra Medizintechnik AG, Hirrlingen, Germany) and Levitronix CentriMag (Levitronix LCC, Waltham, MA) as central or peripheral veno-arterial extracorporeal membrane oxygenation (ECMO) support systems have been investigated as treatment for patients with refractory cardiogenic shock (CS). Methods and Materials Between January 2007 and October 2012, 228 consecutive adult patients were supported on RotaFlow (n=213) or CentriMag (n=15) ECMO, at our institutions (155 men; age 58.3±10.5 years, range: 19-84 years). Indications for support were: failure to wean from cardiopulmonary bypass in the setting of postcardiotomy (n=118) and primary donor graft failure (n=37); post-acute myocardial infarction CS (n=27); acute myocarditis (n=6); and CS on chronic heart failure (n=40). Results A central ECMO setting was established in 102 (44.7%) patients while peripherally in 126 (55.2%). Overall mean support time was 10.9±9.7 days (range: 1-34 days). Eighty-four (36.8%) patients died on ECMO. Overall success rate, in terms of survival on ECMO (n=144), weaning from mechanical support (n=107; 46.9%), bridge to long-term ventricular assist device (n=6; 2.6%) and bridge to heart transplantation (n=31; 13.5%), was 63.1%. Hundred-twenty-two (53.5%) patients were successfully discharged. Stepwise logistic regression identified blood lactate level and CK-MB relative index at 72 h after ECMO initiation, and number of PRBCs transfused on ECMO as significant predictors of mortality on ECMO [p=0.010, odds ratio (OR)=2.94; 95% confidence interval (CI)=1.10–3.14; p=0.010, OR=2.82, 95% CI=1.014 - 3.72; and p=0.011, OR=2.69; 95% CI=1.06–4.16; respectively]. No significant differences were seen by comparing RotaFlow and CentriMag populations in terms of device performance. Conclusions Patients with a poor hemodynamic status may benefit by rapid central and peripheral insertion of ECMO. The blood lactate level, CK-MB relative index and PRBCs transfused should be strictly monitored during ECMO support.
- Published
- 2013
37. Donor-derived Cell-free DNA-Ready for Prime Time Yet?
- Author
-
Ensminger S and Potena L
- Subjects
- Humans, Organ Transplantation, Cell-Free Nucleic Acids blood, Cell-Free Nucleic Acids genetics, Tissue Donors
- Abstract
Competing Interests: The authors declare no funding or conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
38. CTA-Derived Pericoronary Fat Attenuation Index Predicts Allograft Rejection and Cardiovascular Events in Heart Transplant Recipients.
- Author
-
Sansonetti A, Belmonte M, Masetti M, Bergamaschi L, Paolisso P, Borgese L, Angeli F, Armillotta M, Dierckx R, Verstreken S, Gaibazzi N, Tuttolomondo D, Baldovini C, Barbato E, Rucci P, Bartunek J, Potena L, Vanderheyden M, and Pizzi C
- Published
- 2024
- Full Text
- View/download PDF
39. Evaluation of non-invasive biomarkers of kidney allograft rejection in a prospective multicenter unselected cohort study (EU-TRAIN).
- Author
-
Goutaudier V, Danger R, Catar RA, Racapé M, Philippe A, Elias M, Raynaud M, Aubert O, Bouton D, Girardin F, Vicaut É, Yaiche S, Demotes J, Heidecke H, Taupin JL, Randoux-Lebrun C, Zaidan M, Papuchon E, Le Mai H, Nguyen TV, Moreso F, Berney T, Villard J, Legendre C, Dragun D, Papalois V, Potena L, Giral M, Gourraud PA, Brouard S, Crespo E, Halleck F, Budde K, Bestard O, Loupy A, and Lefaucheur C
- Abstract
Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020. We prospectively assessed gene expression levels of 19 blood messenger RNAs, four antibodies targeting non-human leukocyte antigen (HLA) endothelial antigens, together with circulating anti-HLA donor-specific antibodies (DSA). The primary outcome was allograft rejection (antibody-mediated, T cell-mediated, or mixed) in the first year post-transplantation. Overall, 412 patients were included, with 812 biopsies paired with a blood sample. CD4 gene expression was significantly associated with rejection, while circulating anti-HLA DSA had a significant association with allograft rejection and a strong association with antibody-mediated rejection. All other tested biomarkers, including AKR1C3, CD3E, CD40, CD8A, CD9, CTLA4, ENTPD1, FOXP3, GZMB, ID3, IL7R, MS4A1, MZB1, POU2AF1, POU2F1, TCL1A, TLR4, and TRIB1, as well as antibodies against angiotensin II type 1 receptor, endothelin 1 type A receptor, C3a and C5a receptors, did not show significant associations with allograft rejection. The blood messenger RNAs and non-HLA antibodies did not show an additional value beyond standard of care monitoring parameters and circulating anti-HLA DSA to predict allograft rejection in the first year post-transplantation. Thus, our results open avenues for specifically designed studies to demonstrate the clinical relevance and implementation of other candidate non-invasive biomarkers in kidney transplantation practice., (Copyright © 2024 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Prevention and rehabilitation after heart transplantation: A clinical consensus statement of the European Association of Preventive Cardiology, Heart Failure Association of the ESC, and the European Cardio Thoracic Transplant Association, a section of ESOT.
- Author
-
Simonenko M, Hansen D, Niebauer J, Volterrani M, Adamopoulos S, Amarelli C, Ambrosetti M, Anker SD, Bayes-Genis A, Gal TB, Bowen TS, Cacciatore F, Caminiti G, Cavarretta E, Chioncel O, Coats AJS, Cohen-Solal A, D'Ascenzi F, de Pablo Zarzosa C, Gevaert AB, Gustafsson F, Kemps H, Hill L, Jaarsma T, Jankowska E, Joyce E, Krankel N, Lainscak M, Lund LH, Moura B, Nytrøen K, Osto E, Piepoli M, Potena L, Rakisheva A, Rosano G, Savarese G, Seferovic PM, Thompson DR, Thum T, and Van Craenenbroeck EM
- Subjects
- Humans, Quality of Life, Risk Factors, Treatment Outcome, Risk Reduction Behavior, Heart Transplantation adverse effects, Heart Transplantation rehabilitation, Consensus, Heart Failure rehabilitation, Cardiac Rehabilitation
- Abstract
Little is known either about either physical activity patterns, or other lifestyle-related prevention measures in heart transplantation (HTx) recipients. The history of HTx started more than 50 years ago but there are still no guidelines or position papers highlighting the features of prevention and rehabilitation after HTx. The aims of this scientific statement are (i) to explain the importance of prevention and rehabilitation after HTx, and (ii) to promote the factors (modifiable/non-modifiable) that should be addressed after HTx to improve patients' physical capacity, quality of life and survival. All HTx team members have their role to play in the care of these patients and multidisciplinary prevention and rehabilitation programmes designed for transplant recipients. HTx recipients are clearly not healthy disease-free subjects yet they also significantly differ from heart failure patients or those who are supported with mechanical circulatory support. Therefore, prevention and rehabilitation after HTx both need to be specifically tailored to this patient population and be multidisciplinary in nature. Prevention and rehabilitation programmes should be initiated early after HTx and continued during the entire post-transplant journey. This clinical consensus., Competing Interests: Conflict of interest: none declared., (© The Authors 2024. Published by John Wiley & Sons Limited and Oxford University Press on behalf of the European Society of Cardiology, and Frontiers Media SA on behalf of the European Society for Organ Transplantation.)
- Published
- 2024
- Full Text
- View/download PDF
41. Ventilation strategies in cardiogenic shock: Insights from the AltShock-2 registry.
- Author
-
Sacco A, Montisci A, Tavecchia G, Frea S, Bernasconi D, Colombo CNJ, Bertolin S, Viola G, Villanova L, Briani M, Patrini L, Bocchino PP, Sorini Dini C, D'Ettore N, Bertaina M, Iannaccone M, Potena L, Bertoldi L, Valente S, Camporotondo R, Marini M, Pagnesi M, Metra M, De Ferrari G, Oliva F, Morici N, Pappalardo F, and Tavazzi G
- Abstract
Aims: To describe the use and the relation to outcome of different ventilation strategies in a contemporary, large, prospective registry of cardiogenic shock patients., Methods and Results: Among 657 patients enrolled from March 2020 to November 2023, 198 (30.1%) received oxygen therapy (OT), 96 (14.6%) underwent non-invasive ventilation (NIV), and 363 (55.3%) underwent invasive mechanical ventilation (iMV). Patients in the iMV group were significantly younger compared to those in the NIV and OT groups (63 vs. 69 years, p < 0.001). There were no significant differences between groups regarding cardiovascular risk factors. Patients with SCAI B and C were more frequently treated with OT and NIV compared to iMV (65.1% and 65.4% vs. 42.6%, respectively, p > 0.001), while the opposite trend was observed in SCAI D patients (12% and 12.2% vs. 30.9%, respectively, p < 0.001). All-cause mortality at 24 h did not differ amongst the three groups. The 60-day mortality rates were 40.2% for the iMV group, 26% for the OT group, and 29.3% for the NIV group (p = 0.005), even after excluding patients with cardiac arrest at presentation. In the multivariate analysis including SCAI stages, NIV was not associated with worse mortality compared to iMV (hazard ratio 1.97, 95% confidence interval 0.85-4.56), even in more severe SCAI stages such as D., Conclusions: Compared to previous studies, we observed a rising trend in the utilization of NIV among cardiogenic shock patients, irrespective of aetiology and SCAI stages. In this clinical scenario, NIV emerges as a safe option for appropriately selected patients., (© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
42. Redefining the molecular rejection states in 3230 heart transplant biopsies: Relationships to parenchymal injury and graft survival.
- Author
-
Halloran PF, Madill-Thomsen K, Aliabadi-Zuckermann AZ, Cadeiras M, Crespo-Leiro MG, Depasquale EC, Deng M, Gökler J, Hall S, Jamil A, Kim DH, Kobashigawa J, Macdonald P, Melenovsky V, Patel J, Potena L, Shah K, Stehlik J, and Zuckermann A
- Subjects
- Humans, Male, Biopsy, Female, Middle Aged, Follow-Up Studies, Prognosis, Myocardium pathology, Adult, Risk Factors, Heart Transplantation adverse effects, Graft Rejection etiology, Graft Rejection diagnosis, Graft Rejection pathology, Graft Survival
- Abstract
The first-generation Molecular Microscope (MMDx) system for heart transplant endomyocardial biopsies used expression of rejection-associated transcripts (RATs) to diagnose not only T cell-mediated rejection (TCMR) and antibody-mediated rejection (ABMR) but also acute injury. However, the ideal system should detect rejection without being influenced by injury, to permit analysis of the relationship between rejection and parenchymal injury. To achieve this, we developed a new rejection classification in an expanded cohort of 3230 biopsies: 1641 from INTERHEART (ClinicalTrials.gov NCT02670408), plus 1589 service biopsies added to improve the power of the machine learning algorithms. The new system used 6 rejection classifiers instead of RATs and generated 7 rejection archetypes: No rejection, 48%; Minor, 24%; TCMR1, 2.3%; TCMR2, 2.7%; TCMR/mixed, 2.7%; early-stage ABMR, 3.9%; and fully developed ABMR, 16%. Using rejection classifiers eliminated cross-reactions with acute injury, permitting separate assessment of rejection and injury. TCMR was associated with severe-recent injury and late atrophy-fibrosis and rarely had normal parenchyma. ABMR was better tolerated, seldom producing severe injury, but in later biopsies was often associated with atrophy-fibrosis, indicating long-term risk. Graft survival and left ventricular ejection fraction were reduced not only in hearts with TCMR but also in hearts with severe-recent injury and atrophy-fibrosis, even without rejection., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM-HF registry.
- Author
-
Inciardi RM, Vaduganathan M, Lombardi CM, Gussago C, Agostoni P, Ameri P, Aspromonte N, Calò L, Cameli M, Carluccio E, Carugo S, Cipriani M, De Caterina R, De Ferrari GM, Emdin M, Fornaro A, Guazzi M, Iacoviello M, Imazio M, La Rovere MT, Leonardi S, Maccallini M, Masarone D, Moschini L, Palazzuoli A, Patti G, Pedretti RFE, Perrone Filardi P, Piepoli MF, Potena L, Salzano A, Sciacqua A, Senni M, Sinagra G, Specchia C, Taddei S, Vizza D, Savarese G, Rosano G, Volterrani M, and Metra M
- Subjects
- Humans, Prospective Studies, Stroke Volume physiology, Guideline Adherence, Female, Male, Italy epidemiology, Heart Failure drug therapy, Registries
- Abstract
Aims: Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM-HF) registry is designed to evaluate the prevalence of evidence-based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real-world population of consecutive patients with HF across the whole ejection fraction spectrum and among different clinical phenotypes., Methods: The OPTIPHARM-HF registry (NCT06192524) is a prospective, multicenter, observational, national study of adult patients with symptomatic HF, as defined by current international guidelines, regardless of ejection fraction. Both outpatients and inpatients with chronic and acute decompensated HF will be recruited. The study will enroll up to 2500 patients with chronic HF at approximately 35 Italian HF centres. Patients will be followed for a maximum duration of 24 months. The primary objective of the OPTIPHARM-HF registry is to assess prescription and adherence to evidence-based guideline-directed medical therapy (GDMT) in patients with HF. The primary outcome is to describe the prevalence of GDMT use according to target guideline recommendation. Secondary objectives include implementation of comorbidity treatment, evaluation of sequence of treatment introduction and up-titration, description of GDMT implementation in the specific HF population, main causes of GDMT underuse, and assessment of cumulative rate of cardiovascular events., Conclusion: The OPTIPHARM-HF registry will provide important implications for improving patient care and adoption of recommended medical therapy into clinical practice among HF patients., (© 2024 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
44. European Society for Organ Transplantation (ESOT) Consensus Statement on the Use of Non-invasive Biomarkers for Cardiothoracic Transplant Rejection Surveillance.
- Author
-
Nikolova A, Agbor-Enoh S, Bos S, Crespo-Leiro M, Ensminger S, Jimenez-Blanco M, Minervini A, Perch M, Segovia J, Vos R, Khush K, and Potena L
- Subjects
- Humans, Biopsy, Cell-Free Nucleic Acids blood, Consensus, Europe, Gene Expression Profiling, Societies, Medical, Biomarkers blood, Graft Rejection diagnosis, Heart Transplantation, Lung Transplantation adverse effects
- Abstract
While allograft rejection (AR) continues to threaten the success of cardiothoracic transplantation, lack of accurate and repeatable surveillance tools to diagnose AR is a major unmet need in the clinical management of cardiothoracic transplant recipients. Endomyocardial biopsy (EMB) and transbronchial biopsy (TBBx) have been the cornerstone of rejection monitoring since the field's incipience, but both suffer from significant limitations, including poor concordance of biopsy interpretation among pathologists. In recent years, novel molecular tools for AR monitoring have emerged and their performance characteristics have been evaluated in multiple studies. An international working group convened by ESOT has reviewed the existing literature and provides a series of recommendations to guide the use of these biomarkers in clinical practice. While acknowledging some caveats, the group recognized that Gene-expression profiling and donor-derived cell-free DNA (dd-cfDNA) may be used to rule out rejection in heart transplant recipients, but they are not recommended for cardiac allograft vasculopathy screening. Other traditional biomarkers (NT-proBNP, BNP or troponin) do not have sufficient evidence to support their use to diagnose AR. Regarding lung transplant, dd-cfDNA could be used to rule out clinical rejection and infection, but its use to monitor treatment response is not recommended., Competing Interests: KK consulted for Care-Dx; MCL received speakers fees from Care-Dx; LP received lab material from Care-Dx; SB is PI of a Eurofins sponsored study MJB received institutional grant from Eurofins. All other authors declare no conflict of interest with the topic of current manuscript., (Copyright © 2024 Nikolova, Agbor-Enoh, Bos, Crespo-Leiro, Ensminger, Jimenez-Blanco, Minervini, Perch, Segovia, Vos, Khush and Potena.)
- Published
- 2024
- Full Text
- View/download PDF
45. The International Consortium on Primary Graft Dysfunction: Redefining Clinical Risk Factors in the Contemporary Era of Heart Transplantation.
- Author
-
Moayedi Y, Truby LK, Foroutan F, Han J, Guzman J, Angleitner P, Sabatino M, Felius J, VAN Zyl JS, Rodenas-Alesina E, Fan CP, Devore AD, Miller R, Potena L, Zuckermann A, Farrero M, Chih S, Farr M, Hall S, Ross HJ, and Khush KK
- Subjects
- Humans, Female, Male, Retrospective Studies, Risk Factors, Middle Aged, Incidence, Canada epidemiology, Adult, Europe epidemiology, Risk Assessment methods, United States epidemiology, Registries, Heart Failure surgery, Heart Failure epidemiology, Heart Transplantation adverse effects, Heart Transplantation trends, Primary Graft Dysfunction epidemiology, Primary Graft Dysfunction etiology
- Abstract
Background: Primary graft dysfunction (PGD) is the leading cause of morbidity and mortality early after heart transplantation (HT). The International Consortium on PGD is a multicenter collaboration dedicated to identifying the clinical risk factors for PGD in the contemporary era of HT. The objectives of the current report were (1) to assess the incidence of severe PGD in an international cohort; (2) to evaluate the performance of the most strongly validated PGD risk tool, the RADIAL score, in a contemporary cohort; and (3) to redefine clinical risk factors for severe PGD in the current era of HT., Methods: This is a retrospective, observational study of consecutive adult HT recipients between 2010 and 2020 in 10 centers in the United States, Canada and Europe. Patients with severe PGD were compared to those without severe PGD (comprising those with no, mild and moderate PGD). The RADIAL score was calculated for each transplant recipient. The discriminatory power of the RADIAL score was evaluated using receiver operating characteristic (ROC) analysis, and its calibration was assessed by plotting the percentage of PGD predicted vs that which was observed. To identify clinical risk factors associated with severe PGD, we performed multivariable mixed-effects logistic regression modeling to account for among-center variability., Results: A total of 2746 patients have been enrolled in the registry to date, including 2015 (73.4%) from North America, and 731 (26.6%) from Europe; 215 participants (7.8%) met the criteria for severe PGD. There was an increase in the incidence of severe PGD over the study period (P value for trend by difference sign test = 0.004). The Kaplan-Meier estimate for 1-year survival was 75.7% (95% CI 69.4-80.9%) in patients with severe PGD as compared to 94.4% (95% CI 93.5-95.2%) in those without severe PGD (log-rank P value < 0.001). The RADIAL score performed poorly in our contemporary cohort and was not associated with severe PGD; it had an AUC of 0.53 (95% CI 0.48-0.58). In the multivariable regression model, acute preoperative dialysis (OR 2.41, 95% CI 1.31-4.43), durable left ventricular assist device support (OR 1.77, 95% CI 1.13-2.77), and total ischemic time (OR 1.20 for each additional hour, 95% CI 1.02-1.41) were associated with an increased risk of severe PGD., Conclusions: Our consortium has identified an increasing incidence of PGD in the modern transplant era. We identified contemporary risk factors for this early post-transplant complication, which confers a high mortality risk. These results may enable the identification of patients at high risk for developing severe PGD in order to inform peri-transplant donor and recipient management practices., Competing Interests: Disclosures None., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
46. Molecular states associated with dysfunction and graft loss in heart transplants.
- Author
-
Halloran PF, Madill-Thomsen K, Mackova M, Aliabadi-Zuckermann AZ, Cadeiras M, Crespo-Leiro MG, Depasquale EC, Deng M, Gökler J, Hall SA, Kim DH, Kobashigawa J, Macdonald P, Potena L, Shah K, Stehlik J, Zuckermann A, and Reeve J
- Subjects
- Humans, Stroke Volume, Hypoxia, Inflammation, Ventricular Function, Left, Heart Transplantation
- Abstract
Background: We explored the changes in gene expression correlating with dysfunction and graft failure in endomyocardial biopsies., Methods: Genome-wide microarrays (19,462 genes) were used to define mRNA changes correlating with dysfunction (left ventricular ejection fraction [LVEF] ≤ 55) and risk of graft loss within 3 years postbiopsy. LVEF data was available for 1,013 biopsies and survival data for 779 patients (74 losses). Molecular classifiers were built for predicting dysfunction (LVEF ≤ 55) and postbiopsy 3-year survival., Results: Dysfunction is correlated with dedifferentiation-decreased expression of normal heart transcripts, for example, solute carriers, along with increased expression of inflammation genes. Many genes with reduced expression in dysfunction were matrix genes such as fibulin 1 and decorin. Gene ontology (GO) categories suggested matrix remodeling and inflammation, not rejection. Genes associated with the risk of failure postbiopsy overlapped dysfunction genes but also included genes affecting microcirculation, for example, arginase 2, which reduces NO production, and endothelin 1. GO terms also reflected increased glycolysis and response to hypoxia, but decreased VEGF and angiogenesis pathways. T cell-mediated rejection was associated with reduced survival and antibody-mediated rejection with relatively good survival, but the main determinants of survival were features of parenchymal injury. Both dysfunction and graft loss were correlated with increased biopsy expression of BNP (gene NPPB). Survival probability classifiers divided hearts into risk quintiles, with actuarial 3-year postbiopsy survival >95% for the highest versus 50% for the lowest., Conclusions: Dysfunction in transplanted hearts reflects dedifferentiation, decreased matrix genes, injury, and inflammation. The risk of short-term loss includes these changes but is also associated with microcirculation abnormalities, glycolysis, and response to hypoxia., (Copyright © 2024 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Right ventricular dysfunction in left ventricular assist device candidates: is it time to change our prospective?
- Author
-
Sciaccaluga C, Procopio MC, Potena L, Masetti M, Bernazzali S, Maccherini M, Landra F, Righini FM, Cameli M, and Valente S
- Subjects
- Humans, Echocardiography, Retrospective Studies, Heart-Assist Devices adverse effects, Ventricular Dysfunction, Right, Heart Failure surgery, Heart Failure etiology, Heart Transplantation adverse effects
- Abstract
The use of left ventricular assist devices (LVAD) has significantly increased in the last years, trying to offer a therapeutic alternative to heart transplantation, in light also to the significant heart donor shortage compared to the growing advanced heart failure population. Despite technological improvements in the devices, LVAD-related mortality is still fairly high, with right heart failure being one of the predominant predictors. Therefore, many efforts have been made toward a thorough right ventricular (RV) evaluation prior to LVAD implant, considering clinical, laboratory, echocardiographic, and invasive hemodynamic parameters. However, there is high heterogeneity regarding both which predictor is the strongest as well as the relative cut-off values, and a consensus has not been reached yet, increasing the risk of facing patients in which the distinction between good or poor RV function cannot be surely reached. In parallel, due to technological development and availability of mechanical circulatory support of the RV, LVADs are being considered even in patients with suboptimal RV function. The aim of our review is to analyze the current evidence regarding the role of RV function prior to LVAD and its evaluation, pointing out the extreme variability in parameters that are currently assessed and future prospective regarding new diagnostic tools. Finally, we attempt to gather the available information on the therapeutic strategies to use in the peri-operative phase, in order to reduce the incidence of RV failure, especially in patients in which the preoperative evaluation highlighted some conflicting results with regard to ventricular function., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
48. Transitioning to Palliative Care in an Italian Cardiac Intensive Care Unit Network.
- Author
-
Sacco A, Pagnesi M, Frea S, Briani M, Dini CS, Bertaina M, Marini M, Trombara F, Villanova L, Ravera A, Tavazzi G, Pappalardo F, Morici N, and Potena L
- Subjects
- Humans, Palliative Care, Shock, Cardiogenic, Death, Intensive Care Units, Italy, Terminal Care methods, Defibrillators, Implantable, Heart Failure therapy
- Abstract
Background: Recent data indicate that end-of-life management for patients affected by acute decompensated heart failure in cardiac intensive care units is aggressive, with late or no engagement of palliative care teams., Objective: To assess current palliative care and end-of-life practices in a contemporary Italian multicenter registry of patients with cardiogenic shock due to acute decompensated heart failure., Methods: A survey-based approach was used to collect data on palliative care and end-of-life management practices. The AltShock-2 registry enrolled patients with cardiogenic shock from 12 participating centers. A subset of 153 patients with cardiogenic shock due to acute decompensated heart failure enrolled between March 2020 and March 2023 was analyzed, with a focus on early engagement of palliative care teams and deactivation of implantable cardioverter-defibrillators (ICDs)., Results: "Do not resuscitate" orders were documented in patient records in only 5 of 12 centers (42%). Palliative care teams were engaged for 21 of 153 enrolled patients (13.7%). Among the 51 patients with ICDs, 6 of 17 patients who died (35%) had defibrillator deactivation. Of the 17 patients who died, 13 died in the hospital and 4 died within 6 months after discharge; 1 patient had ICD deactivation supported by palliative care services at home., Conclusions: Therapy-limiting practices, including ICD deactivation, are not routine in the Italian centers participating in this study. The results emphasize the importance of integrating palliative care as a simultaneous process with intensive care to address the unmet needs of these patients and their families., (©2024 American Association of Critical-Care Nurses.)
- Published
- 2024
- Full Text
- View/download PDF
49. Socioeconomic deprivation and heart transplantation: A call for progress in the United States and EUROPE.
- Author
-
Grossi AA, Potena L, Rossano JW, and Breathett K
- Subjects
- Humans, United States, Europe, Socioeconomic Factors, Heart Transplantation
- Published
- 2024
- Full Text
- View/download PDF
50. Biologic treatment of psoriasis in solid organ transplant recipients.
- Author
-
Guglielmo A, Pileri A, Toniutto P, Bardazzi F, Potena L, Russo A, Masetti M, Maria Piraccini B, and Stinco G
- Subjects
- Humans, Organ Transplantation, Psoriasis drug therapy, Biological Products therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.